Intrahepatic expression of pre-S 1 and pre-S2 antigens in chronic hepatitis B virus infection in relation to hepatitis B virus replication and hepatitis delta virus superinfection C M Chu, Y F Liaw Abstract Hepatocyte expression of pre-SI and pre-S2 in relation to hepatitis B virus replication (hepatitis B virus-DNA in serum and HBcAg in the liver), histological activity and hepatitis delta virus superinfection was studied by indirect immunofluorescence on frozen sections of liver specimens from 68 patients with chronic hepatitis B virus infection. All 44 patients with chronic type B hepatitis had preSi and pre-S2 display in the liver. The distribution of pre-SI in the liver was membranous in one, mixed membranous and cytoplasmic in 12, and cytoplasmic in 31 . The distribution of pre-S2 was membranous in one, mixed membranous and cytoplasmic in 26, and cytoplasmic in 17. Membranous expression of preSi was significantly more prevalent in patients with active hepatitis B virus replication than in those without (13/28 v 0/16, p<O.OOl), regardless of the histological activity, as was membranous expression of pre-S2 (27/28 v 0/16, p<O-OOl). In contrast, a significantly higher extent of cytoplasmic expression of pre-Sl and pre-S2 was noted in patients without active hepatitis B virus replication than in those with. Of 24 Table I *p<0.001, tp<O0O1 (by X2 test with Yates' correction). Cytoplasmic expression ofpre-S 1 and pre-S2 was noted in 43 and 43 patients, respectively. Semiquantitative analysis revealed that the degrees of cytoplasmic expression of pre-S 1 as well as pre-S2 were significantly higher in patients without active hepatitis B virus replication than in those with (Table III) .
Of the 24 patients with chronic type D hepatitis, eight were positive for hepatitis B virus-DNA in serum and HBcAg in the liver, and the remainder 16 were negative for both. Table IV shows the distribution of pre-SI and pre-S2 in the liver in chronic hepatitis delta virus infection. Membranous expression of pre-S 1 and pre-S2 correlated significantly with active hepatitis B virus replication. Moreover, a significantly higher degree of cytoplasmic expression of preSi and pre-S2 was noted in patients without active hepatitis B virus replication than in those with (Table V) . The distribution and quantitative expression of pre-S 1 and pre-S2 in the liver in patients with chronic type D hepatitis were comparable with those without hepatitis delta virus infection.
Discussion
The present results showed that all patients with chronic hepatitis B virus infection had pre-S 1 or pre-S2 detectable in the liver, irrespective of the status of hepatitis B virus replication or histological activity. These findings are in keeping with the previous observations,'2 31517 1920 but are in contrast with the suggestion by other groups that the expression of pre-S 1 or pre-S2 in liver varied with the status ofhepatitis B virus replication.7 141618 This discrepancy may be because of the difference in the choice of antisera, tissue manipulation or staining protocols. Furthermore, the expression of HBsAg in liver was essentially identical to that of pre-S2 but not that of pre-S1, in keeping with the suggestion that transcription of mRNAs for HBsAg and pre-S2 is controlled by the same promotor, and that for pre-S 1 is controlled independently by a second Tables I and II . For scales of 0 to 4+, see Table III. *p<O-00l, tp<0-001, and no significant difference (p>0-05) between pre-S2 and pre-Sl expression in each subgroup (by Wilcoxon's rank-sum test).
promotor.2122 This observation also implies that there is control at the level of translation of pre-S2 v HBsAg. Perhaps the more important finding of the present study is that the distribution and quantitative expression ofpre-S 1 and pre-S2 in the liver differed remarkably with the status ofhepatitis B virus replication. During active replication of hepatitis B virus, nearly all patients had pre-S2 expression on the plasma membrane, regardless of serum HBeAg or liver inflammatory activity. Similarly, membranous expression ofpre-S 1 also correlated significantly with active hepatitis B virus replication (Table II) . Previous studies by others have shown a close association between high levels of pre-S 1 or pre-S2 in serum with hepatitis B virus-DNA in serum,4 7-12 in keeping with the observation that pre-S 1 and pre-S2 are the essential components of complete virion.34 Taken together, it seems that, membranous expression of pre-S1 or pre-S2 in the liver is closely related to its presence in serum, and thus might reflect the secretion ofthe hepatitis B virus particles containing pre-S peptides by liver into the circulation, suggesting a pathway through membranous system in assembly or secretion of hepatitis B virus particles. On the contrary, in patients without active hepatitis B virus replication, there is little or no membranous expression of pre-Sl or pre-S2, and, moreover, cytoplasmic expression of pre-S peptides increased remarkably compared with those with active hepatitis B virus replication (Table III) . These findings might suggest that in the non-replicative phase of chronic hepatitis B virus infection, pre-S 1 or pre-S2 is non-secretable, and thus will be retained within the cytoplasm of the hepatocytes. The reason for the relatively less prevalence of pre-S 1 than of pre-S2 on the liver cell membrane during active hepatitis B virus replication, as shown in Table II , is not clear. A similar finding, however, has been reported recently by Suzuki et al. 20 It remains possible that monoclonal antibody against pre-S 1 used in the present study has less affinity to the plasma membrane of hepatocyte than that against pre-S2.
The mechanism responsible for secretion or intracellular retention of pre-S peptides in chronic hepatitis B virus infection is uncertain. Studies in cultured cells have suggested that the cosecretion or the inhibition of secretion of HBsAg/pre-S2 and pre-S 1 might depend on their relative concentrations. 23 24 On the other hand, it has been suggested that, unlike HBsAg, the pre-S peptides do not undergo the spontaneous budding process; rather the initiation of budding might be triggered by interaction with the nucleocapsid or matrix components of the virus.232432 It seems more likely that, in the absence ofactive hepatitis B virus replication and intracellular nucleocapsid protein (HBcAg), surplus pre-S peptides can not migrate to the plasma membrane as part of new assembling particles and thus will accumulate in the cytoplasm.
Several studies have shown a close association between liver inflammatory activities and membrane associated pre-S 1 or pre-S2 in chronic hepatitis B virus infection, suggesting that membranous pre-Sl or pre-S2 might be a possible target antigen in T-cell mediated lysis of hepatocytes." 116 Studies of the in vitro microcytotoxicity assays, however, have suggested hepatitis B virus capsid protein, rather than envelope protein, as a target viral antigen. 33 The present results revealed that membranous expression of pre-S 1 or pre-S2 was found in patients with hepatitis B virus-DNA in serum or HBcAg in liver, regardless of the histological activity, suggesting that membranous expression of pre-S 1 or pre-S2 is closely related to active replication of hepatitis B virus, rather than the extent of liver inflammatory activity.
With regard to the interference of pre-S 1 or pre-S2 expression in the liver in chronic hepatitis delta virus infection, a recent study by Hadziyannis et al34 has suggested that intrahepatic expression of pre-S peptides in chronic hepatitis delta virus infection appeared to be independent of hepatitis B virus and hepatitis delta virus replicative status. In the Hadziyannis's series, however, the vast majority of patients were negative for HBeAg in serum or HBcAg in the liver, and there was no quantitative data of pre-S peptide expression in the liver. The present results showed that the topographic distribution of pre-S 1 and pre-S2 in the liver in HBsAg carriers with hepatitis delta virus infection correlated significantly with the status of hepatitis B virus replication (Table IV) , and that, moreover, the distribution and quantitative expression of pre-SI and pre-S2 were comparable with the hepatitis delta virus negative patients (Tables III, V) . These findings suggested that in HBsAg carriers with chronic hepatitis delta virus infection the synthesis and expression of pre-S peptides in liver correlated closely with the underlying hepatitis B virus replicative status and did not appear to be modulated by the concurrent hepatitis delta virus infection.
In conclusion, the present results suggested that all patients with chronic hepatitis B virus infection had pre-S1 or pre-S2 display in the liver. The distribution and quantitative expression of pre-S peptides in the liver, however, were closely related to the status of hepatitis B virus replication, but not to the histological activity. Concurrent hepatitis delta virus superinfection did not appear to modulate the synthesis and expression of pre-S peptides in the liver. 
